Novel pharmacotherapy for fibromyalgia

Patrick B. Wood, Andrew J. Holman, Kim Jones

    Research output: Contribution to journalArticle

    21 Citations (Scopus)

    Abstract

    Fibromyalgia is a common disorder that is characterized by chronic wide-spread pain, tenderness to light palpation, fatigue and sleep disturbances. The present lack of a well-accepted model of the disorder has hampered progress towards adequate treatment. A review of potential models to explain the pathophysiology underlying its primary symptom (i.e., chronic widespread pain) lends insight on the therapeutic potential of novel therapies. Following this, a mechanistic evaluation of those medications that are under consideration for the treatment of the disorder is offered. Adequate treatment will be likely to involve the identification of biologic sub-groups within the greater fibromyalgia construct. Key insights from basic research are the basis for increased optimism for effective relief among patients and clinicians.

    Original languageEnglish (US)
    Pages (from-to)829-841
    Number of pages13
    JournalExpert Opinion on Investigational Drugs
    Volume16
    Issue number6
    DOIs
    StatePublished - Jun 2007

    Fingerprint

    Fibromyalgia
    Drug Therapy
    Therapeutics
    Palpation
    Chronic Pain
    Fatigue
    Sleep
    Light
    Pain
    Research

    Keywords

    • Central sensitization
    • Chronic widespread pain
    • Descending inhibition
    • Dopamine
    • Fibromyalgia

    ASJC Scopus subject areas

    • Pharmacology

    Cite this

    Novel pharmacotherapy for fibromyalgia. / Wood, Patrick B.; Holman, Andrew J.; Jones, Kim.

    In: Expert Opinion on Investigational Drugs, Vol. 16, No. 6, 06.2007, p. 829-841.

    Research output: Contribution to journalArticle

    Wood, Patrick B. ; Holman, Andrew J. ; Jones, Kim. / Novel pharmacotherapy for fibromyalgia. In: Expert Opinion on Investigational Drugs. 2007 ; Vol. 16, No. 6. pp. 829-841.
    @article{c1d8033d3ec44e53b6f219ceea449880,
    title = "Novel pharmacotherapy for fibromyalgia",
    abstract = "Fibromyalgia is a common disorder that is characterized by chronic wide-spread pain, tenderness to light palpation, fatigue and sleep disturbances. The present lack of a well-accepted model of the disorder has hampered progress towards adequate treatment. A review of potential models to explain the pathophysiology underlying its primary symptom (i.e., chronic widespread pain) lends insight on the therapeutic potential of novel therapies. Following this, a mechanistic evaluation of those medications that are under consideration for the treatment of the disorder is offered. Adequate treatment will be likely to involve the identification of biologic sub-groups within the greater fibromyalgia construct. Key insights from basic research are the basis for increased optimism for effective relief among patients and clinicians.",
    keywords = "Central sensitization, Chronic widespread pain, Descending inhibition, Dopamine, Fibromyalgia",
    author = "Wood, {Patrick B.} and Holman, {Andrew J.} and Kim Jones",
    year = "2007",
    month = "6",
    doi = "10.1517/13543784.16.6.829",
    language = "English (US)",
    volume = "16",
    pages = "829--841",
    journal = "Current Opinion in Investigational Drugs",
    issn = "1354-3784",
    publisher = "Informa Healthcare",
    number = "6",

    }

    TY - JOUR

    T1 - Novel pharmacotherapy for fibromyalgia

    AU - Wood, Patrick B.

    AU - Holman, Andrew J.

    AU - Jones, Kim

    PY - 2007/6

    Y1 - 2007/6

    N2 - Fibromyalgia is a common disorder that is characterized by chronic wide-spread pain, tenderness to light palpation, fatigue and sleep disturbances. The present lack of a well-accepted model of the disorder has hampered progress towards adequate treatment. A review of potential models to explain the pathophysiology underlying its primary symptom (i.e., chronic widespread pain) lends insight on the therapeutic potential of novel therapies. Following this, a mechanistic evaluation of those medications that are under consideration for the treatment of the disorder is offered. Adequate treatment will be likely to involve the identification of biologic sub-groups within the greater fibromyalgia construct. Key insights from basic research are the basis for increased optimism for effective relief among patients and clinicians.

    AB - Fibromyalgia is a common disorder that is characterized by chronic wide-spread pain, tenderness to light palpation, fatigue and sleep disturbances. The present lack of a well-accepted model of the disorder has hampered progress towards adequate treatment. A review of potential models to explain the pathophysiology underlying its primary symptom (i.e., chronic widespread pain) lends insight on the therapeutic potential of novel therapies. Following this, a mechanistic evaluation of those medications that are under consideration for the treatment of the disorder is offered. Adequate treatment will be likely to involve the identification of biologic sub-groups within the greater fibromyalgia construct. Key insights from basic research are the basis for increased optimism for effective relief among patients and clinicians.

    KW - Central sensitization

    KW - Chronic widespread pain

    KW - Descending inhibition

    KW - Dopamine

    KW - Fibromyalgia

    UR - http://www.scopus.com/inward/record.url?scp=34250013888&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=34250013888&partnerID=8YFLogxK

    U2 - 10.1517/13543784.16.6.829

    DO - 10.1517/13543784.16.6.829

    M3 - Article

    VL - 16

    SP - 829

    EP - 841

    JO - Current Opinion in Investigational Drugs

    JF - Current Opinion in Investigational Drugs

    SN - 1354-3784

    IS - 6

    ER -